Search - tctmd.com

Displaying 141 - 160 of 255

Sort: Relevancy | Date

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

Caitlin E. Cox

September 01, 2015

News Daily News

年长房颤 PCI 患者在接受三联疗法时，其血栓状况未得到改善，且出血事件增加

August 04, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Daily News

El Tratamiento Triple No ofrece Beneficio Trombótico y Sí Más Hemorragias en Pacientes Ancianos con FA sometidos a PCI

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Daily News

Los IAM secundarios a Embolismos Coronarios son Raros y Suelen Asociarse a la FA

L.A. McKeown

July 08, 2015

News Daily News

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

L.A. McKeown

July 08, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

June 25, 2015

News Daily News

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

June 25, 2015

News Daily News

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

June 09, 2015

News Daily News

Bivalirudina + GPI Reduce las Hemorragias y Mortalidad de Pacientes con ICC sometidos a PCI

June 09, 2015

Advertisement

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

NSAIDs Plus Anticoagulants a Bad Combination

年长房颤 PCI 患者在接受三联疗法时，其血栓状况未得到改善，且出血事件增加

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

El Tratamiento Triple No ofrece Beneficio Trombótico y Sí Más Hemorragias en Pacientes Ancianos con FA sometidos a PCI

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

UK launch for Daiichi's bloodthinner Lixiana

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

Los IAM secundarios a Embolismos Coronarios son Raros y Suelen Asociarse a la FA

Acute MI Arising From Coronary Embolism Rare, Often Tied to A-fib

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

Bivalirudin Plus GPI Cuts Bleeding, Mortality in Heart Failure Patients Undergoing PCI

Bivalirudina + GPI Reduce las Hemorragias y Mortalidad de Pacientes con ICC sometidos a PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content